scholarly journals Cardiac Period 2 in myocardial ischemia: Clinical implications of a light dependent protein

2013 ◽  
Vol 45 (3) ◽  
pp. 667-671 ◽  
Author(s):  
Stephanie Bonney ◽  
Kelly Hughes ◽  
Patrick N. Harter ◽  
Michel Mittelbronn ◽  
Lori Walker ◽  
...  
1997 ◽  
Vol 29 (4) ◽  
pp. 756-763 ◽  
Author(s):  
Craig R Narins ◽  
Wojciech Zareba ◽  
Arthur J Moss ◽  
Robert E Goldstein ◽  
W.Jackson Hall

1999 ◽  
Vol 276 (2) ◽  
pp. H642-H650 ◽  
Author(s):  
Carolyn J. Albert ◽  
David A. Ford

The present study demonstrates that the α, ε, and ι isozymes of protein kinase C (PKC) are translocated to particulate fractions from the cytosol during brief intervals of global ischemia as well as reperfusion of ischemic rat myocardium. In contrast, phorbol ester treatment of perfused hearts resulted in the translocation of the α, δ, and ε isozymes of PKC to particulate fractions. Additionally, the α, δ, and ε isozymes of PKC are translocated to particulate fractions in phorbol ester-stimulated, isolated adult rat cardiac myocytes. Concomitant with the translocation of PKC isozymes to particulate fractions during myocardial ischemia, increased protein phosphorylation was observed, which was blocked by pretreatment of hearts with the selective PKC inhibitor bisindolylmaleimide I (50 nM). In particular, ischemia resulted in the phosphorylation of 26-, 20-, and 17-kDa particulate-associated proteins. Taken together, the present findings are the first to demonstrate that specific PKC isozymes are translocated to particulate fractions in the ischemic and the reperfused ischemic rat heart, resulting in the phosphorylation of specific particulate-associated proteins.


1986 ◽  
Vol 18 ◽  
pp. 41-41
Author(s):  
W KUBLER ◽  
R DIETZ ◽  
B KRAMER ◽  
W MAURER ◽  
A SCHOMIG

2007 ◽  
Vol 119 (3) ◽  
pp. 283-290 ◽  
Author(s):  
Nazar Luqman ◽  
Ruey J. Sung ◽  
Chun-Li Wang ◽  
Chi-Tai Kuo

2018 ◽  
Vol 24 (28) ◽  
pp. 3376-3383 ◽  
Author(s):  
Yoshimasa Oyama ◽  
Colleen Marie Bartman ◽  
Jennifer Gile ◽  
Daniel Sehrt ◽  
Tobias Eckle

Background: Recently, we identified the circadian rhythm protein Period 2 (PER2) in robust cardioprotection from myocardial ischemia (MI). Based on findings that perioperative MI is the most common major cardiovascular complication and that anesthetics can alter the expression of PER2, we hypothesized that an anesthesia mediated downregulation of PER2 could be detrimental if myocardial ischemia and reperfusion (IR) would occur. Methods: and Results: We exposed mice to pentobarbital, fentanyl, ketamine, propofol, midazolam or isoflurane and determined cardiac Per2 mRNA levels. Unexpectedly, only midazolam treatment resulted in an immediate and significant downregulation of Per2 transcript levels. Subsequent studies in mice pretreated with midazolam using an in-situ mouse model for myocardial (IR)-injury revealed a significant and dramatic increase in infarct sizes or Troponin-I serum levels in the midazolam treated group when compared to controls. Using the recently identified flavonoid, nobiletin, as a PER2 enhancer completely abolished the deleterious effects of midazolam during myocardial IR-injury. Moreover, nobiletin treatment alone significantly reduced infarct sizes or Troponin I levels in wildtype but not in Per2-/- mice. Pharmacological studies on nobiletin like flavonoids revealed that only nobiletin and tangeritin, both found to enhance PER2, were cardioprotective in our murine model for myocardial IR-injury. Conclusion: We identified midazolam mediated downregulation of cardiac PER2 as an underlying mechanism for a deleterious effect of midazolam pretreatment in myocardial IR-injury. These findings highlight PER2 as a cardioprotective mechanism and suggest the PER2 enhancers nobiletin or tangeritin as a preventative therapy for myocardial IR-injury in the perioperative setting where midazolam pretreatment occurs frequently.


2016 ◽  
Vol 89 (3) ◽  
pp. 319-321 ◽  
Author(s):  
Simona Roxana Gheorghe ◽  
Alexandra Mărioara Crăciun

Matrix Gla protein is a vitamin K-dependent protein secreted by chondrocytes and vascular smooth muscle cells. The presence of matrix Gla protein was reported in arterial and venous walls, lungs, kidney, uterus, heart, tooth cementum and eyes. Several studies identified matrix Gla protein in tumoral pathology.Until recently, it was thought to only have an inhibitory role of physiological and ectopic calcification. New studies demonstrated that it also has a role in physiological and pathological angiogenesis, as well as in tumorigenesis.The aim of this review is to report the latest findings related to the expression and clinical implications of matrix Gla protein in different types of cancer with an emphasis on cerebral tumors.


Sign in / Sign up

Export Citation Format

Share Document